New brain imaging agent could improve Alzheimer's detection
NCT ID NCT06439992
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new radioactive tracer called 18F-Fluselenamyl for PET scans to safely detect amyloid plaques in the brain, a hallmark of Alzheimer's disease. Researchers will compare it to an existing tracer in 60 healthy volunteers and people with mild cognitive impairment or Alzheimer's. The goal is to see if the new tracer is safe and effective for diagnosing Alzheimer's.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple questionnaire empower dementia caregivers after hospital stays?
- Could your heart hold the key to Alzheimer's prevention?
- Can a nudge in your chart unlock Life-Saving genetic clues?
- Can a Voice-Based app map healthy brain aging across 80 years?
- Can MRI reveal the Brain's response to deep brain stimulation?
- Can brain scans and gut bacteria reveal Alzheimer's secrets?